ISSCA Global Summit 2026 panels question peptide quality and clinical evidence
ISSCA says speakers at its 2026 summit raised concerns about product quality, thin clinical evidence and patient-specific protocols for prescribed peptides.
Recap by typeshit. Post by @issca.us on Instagram.